eXoZymes prices $5.33 million stock-and-warrant offering

eXoZymes said June 10, 2026, it priced a public offering of units made up of common stock and warrants, with gross proceeds expected to total about $5.33 million before fees. The biotech company plans to use the money for NCT development, research and development and general corporate purposes.

Why it matters: - The offering gives eXoZymes fresh capital to fund its N-trans-caffeoyltyramine, or NCT, programs and broader research pipeline. - The deal also adds another financing layer through warrants, which could bring in more cash later if exercised. - eXoZymes, which describes itself as an AI-enhanced enzyme company, is using the capital to support development work tied to its biomanufacturing platform.

What happened: - eXoZymes priced a public offering of units on June 10, 2026. - Each unit includes two shares of common stock and one common stock purchase warrant. - The company sold 592,270 shares of common stock together with 296,135 warrants as units. - The public offering price was $18.00 per unit. - Gross proceeds are expected to be about $5.33 million before underwriting discounts, commissions and estimated offering expenses. - The offering is expected to close on June 9, 2026, subject to customary closing conditions. - MDB Capital is serving as underwriter and sole book-running manager.

The details: - The units separate immediately upon issuance, and the shares and warrants will trade as separate securities. - eXoZymes granted the underwriter a 45-day option to buy up to 44,420 additional units at the same unit price, less underwriting discounts and commissions, to cover over-allotments. - Each warrant becomes exercisable on the first anniversary of the offering date. - The warrant exercise price is $11.24 per share. - Each warrant expires five years after issuance. - The company may redeem the warrants for $0.01 per underlying share once they are exercisable if the common stock trades at $17.98 or higher on 20 trading days during any 30-trading-day period, subject to stock split and recapitalization adjustments. - The warrant exercise price may reset to $0.001 per underlying share if, within 12 months of the offering, the company sells additional common stock, preferred stock or other convertible securities below $8.99 per share. - To qualify for a reset, the original purchaser must hold all shares bought in the offering until the reset event. - The warrants will not be listed on any national trading market or other trading medium. - eXoZymes plans to use the net proceeds for NCT opportunities, products developed under the NCT technology, next-in-line products, research and development, working capital and capital expenditures. - The securities are being offered under a Form S-3 registration statement that became effective Jan. 23, 2026. - Copies of the final prospectus supplement, when available, may be obtained from MDB Capital at 14135 Midway Road, Suite G-150, Addison, Texas 75001. - The final prospectus supplement will be filed with the SEC and posted on the SEC’s website at the SEC filing.

Between the lines: - The structure of the deal gives eXoZymes immediate capital while leaving room for additional dilution if warrants are exercised. - The warrant reset feature can make the securities more complex for investors because future financings could change the economics. - The company is continuing to position its exozymes platform as a scalable alternative to petrochemical and cell-based production methods.

What's next: - The offering is expected to close after customary closing conditions are satisfied. - eXoZymes will file the final prospectus supplement with the SEC when available. - The company may receive additional proceeds if the underwriter exercises its over-allotment option or if warrants are later exercised.

The bottom line: - eXoZymes is raising capital now to push forward its NCT and biomanufacturing programs, while giving investors a stock-and-warrant structure that could create more upside and more dilution later.